3 completed. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 1 | Completed 1 |
Follow imdevimab: new trials by email Literature Review of imdevimab trials Research Report on imdevimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers Casirivimab+Imdevimab - Healthy, Chronic Stable Illness | Phase 1 | Completed | Regeneron Pharmaceuticals | 45 | 2022-01-07 | 2025-10-14 |
| Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19 REGN10933+REGN10987, Placebo - Healthy, Chronic Stable Illness | Phase 1 | Completed | Regeneron Pharmaceuticals | 974 | 2020-07-26 | 2022-01-26 |
| Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19 REGN10933+REGN10987 combination therapy, Placebo - COVID-19 | Phase 1 / Phase 2 | Completed | Regeneron Pharmaceuticals | 2252 | 2020-06-10 | 2023-01-27 |
COVID-19 (3) · Coronavirus Infections (1) · Respiratory Distress Syndrome (1)
United States (3) · Brazil (1) · Chile (1) · Mexico (1) · Moldova (1) · Romania (1)
PMID 34473343, PMID 35713300, PMID 35895508, PMID 36255239, PMID 37229174